PetIQ Inc (NASDAQ:PETQ) CEO Mccord Christensen sold 13,652 shares of the company’s stock in a transaction on Friday, June 15th. The stock was sold at an average price of $23.00, for a total transaction of $313,996.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.
Mccord Christensen also recently made the following trade(s):
Get PetIQ alerts:
On Tuesday, June 19th, Mccord Christensen sold 6,348 shares of PetIQ stock. The stock was sold at an average price of $23.01, for a total transaction of $146,067.48. On Monday, April 2nd, Mccord Christensen sold 20,000 shares of PetIQ stock. The stock was sold at an average price of $26.22, for a total transaction of $524,400.00.
Shares of NASDAQ:PETQ opened at $23.96 on Friday. PetIQ Inc has a 1 year low of $17.03 and a 1 year high of $28.23. The company has a quick ratio of 1.09, a current ratio of 2.35 and a debt-to-equity ratio of 0.69.
PetIQ (NASDAQ:PETQ) last released its quarterly earnings results on Tuesday, May 15th. The company reported $0.09 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.05 by $0.04. PetIQ had a net margin of 0.17% and a return on equity of 11.39%. The company had revenue of $115.10 million during the quarter, compared to analysts’ expectations of $108.54 million. The firm’s revenue for the quarter was up 71.8% compared to the same quarter last year. sell-side analysts predict that PetIQ Inc will post 0.78 EPS for the current year.
A number of equities research analysts recently issued reports on PETQ shares. BidaskClub cut shares of PetIQ from a “hold” rating to a “sell” rating in a report on Friday, May 4th. Zacks Investment Research cut shares of PetIQ from a “buy” rating to a “hold” rating in a report on Tuesday, March 27th. Finally, Jefferies Financial Group reiterated a “buy” rating and issued a $30.00 price objective on shares of PetIQ in a report on Wednesday, May 16th. One research analyst has rated the stock with a hold rating and seven have given a buy rating to the company’s stock. PetIQ has a consensus rating of “Buy” and an average target price of $28.00.
A number of hedge funds have recently added to or reduced their stakes in PETQ. Park West Asset Management LLC acquired a new position in shares of PetIQ during the fourth quarter valued at about $19,527,000. Redwood Investments LLC raised its position in shares of PetIQ by 55.5% during the first quarter. Redwood Investments LLC now owns 749,611 shares of the company’s stock valued at $19,940,000 after buying an additional 267,430 shares during the last quarter. Fiera Capital Corp acquired a new position in shares of PetIQ during the first quarter valued at about $6,651,000. Cooper Creek Partners Management LLC raised its position in shares of PetIQ by 192.3% during the fourth quarter. Cooper Creek Partners Management LLC now owns 366,801 shares of the company’s stock valued at $8,011,000 after buying an additional 241,292 shares during the last quarter. Finally, BlackRock Inc. raised its position in shares of PetIQ by 54.6% during the fourth quarter. BlackRock Inc. now owns 632,556 shares of the company’s stock valued at $13,815,000 after buying an additional 223,502 shares during the last quarter. Institutional investors own 63.95% of the company’s stock.
PetIQ Company Profile
PetIQ, Inc develops, manufactures, and distributes pet medications, and health and wellness products for dogs and cats in the United States, Canada, and Europe. It offers pet prescription medications, including products for arthritis, thyroid, and diabetes and pain treatments, as well as heartworm preventatives, antibiotics, and other specialty medications; over-the-counter medications and supplies, such as flea and tick control products in various forms comprising spot on treatments, chewables, and collars; and health and wellness products consisting of specialty treats and other pet products, which include dental treats and nutritional supplements.